- Home
- HYPR vs ANL Comparison
HYPR vs ANL Comparison
Compare HYPR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYPR | ANL |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | HYPR | ANL |
|---|---|---|
| Price | $1.00 | $1.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $1.28 | N/A |
| AVG Volume (30 Days) | ★ 594.5K | 28.5K |
| Earning Date | 11-13-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,591,000.00 | N/A |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $35.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.88 |
| 52 Week High | $2.22 | $2.99 |
Technical Indicators
Market Signals| Indicator | HYPR | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 51.04 |
| Support Level | $0.85 | $0.88 |
| Resistance Level | $1.10 | $1.59 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 44.59 | 70.48 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.